Please provide your email address to receive an email when new articles are posted on . A multidisciplinary approach is key to treating patients with corneal nerve dysfunction and neuropathic ocular ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients who received urcosimod for 12 weeks had a ...

Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo group These findings suggest that ...

Urcosimod ophthalmic solution (0.05% and 0.1%) is currently being evaluated in a phase 2 trial in patients aged 18 years and older with neuropathic corneal pain. The Food and Drug Administration (FDA) ...

Urcosimod is currently being evaluated in a phase 2 trial evaluating it's efficacy and safety in adults with neuropathic corneal pain. OKYO Pharma has filed a Fast Track designation application with ...

The Company anticipates completing enrollment of the 48-patient trial by the end of 2Q 2025 and releasing top-line data on the Phase 2a trial in 4Q 2025. Results from this trial are anticipated to be ...

Have you ever had a migraine attack that felt like something was punching or stabbing you from behind the eyes? You’re not alone! Pain behind the eyes is a common symptom in migraine attacks. Keep ...